NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression
| Autor: | David Mengel, Tze How Mok, Akin Nihat, Wen Liu, Robert A. Rissman, Douglas Galasko, Henrik Zetterberg, Simon Mead, John Collinge, Dominic M. Walsh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Simoa-immunoassays blood [Creutzfeldt-Jakob Syndrome] blood [Neurofilament Proteins] Creutzfeldt-Jakob Syndrome 0302 clinical medicine Neurofilament Proteins Biology (General) Aged 80 and over Immunoassay 0303 health sciences blood [Biomarkers] diagnosis [Alzheimer Disease] pathology [Neurodegenerative Diseases] neurodegeneration Neurodegenerative Diseases General Medicine cerebrospinal fluid [Creutzfeldt-Jakob Syndrome] Middle Aged genetics [Neurofilament Proteins] 3. Good health cerebrospinal fluid [Alzheimer Disease] neurofilament light chain cerebrospinal fluid [Biomarkers] Disease Progression biomarker Female Alzheimer’s disease Adult blood [tau Proteins] QH301-705.5 prion disease diagnosis [Creutzfeldt-Jakob Syndrome] tau Proteins Article cerebrospinal fluid 03 medical and health sciences blood [Alzheimer Disease] Alzheimer Disease blood ddc:570 mental disorders Humans neurofilament protein L 030304 developmental biology Aged nervous system diseases cerebrospinal fluid [Neurofilament Proteins] genetics [tau Proteins] cerebrospinal fluid [tau Proteins] blood [Neurodegenerative Diseases] genetics [Neurodegenerative Diseases] cerebrospinal fluid [Neurodegenerative Diseases] 030217 neurology & neurosurgery Biomarkers |
| Zdroj: | Cells 10(12), 3514 (2021). doi:10.3390/cells10123514 special issue: "Biomarkers of Alzheimer’s Disease: New Insights" Cells Cells; Volume 10; Issue 12; Pages: 3514 Cells, Vol 10, Iss 3514, p 3514 (2021) |
| DOI: | 10.3390/cells10123514 |
| Popis: | This study investigates the diagnostic and prognostic potential of different forms of tau in biofluids from patients with Creutzfeldt-Jakob disease (CJD). Extracellular tau, which is molecularly heterogeneous, was measured using ultra-sensitive custom-made Simoa assays for N-terminal (NT1), mid-region, and full-length tau. We assessed cross-sectional CSF and plasma from healthy controls, patients with Alzheimer’s disease (AD) and CJD patients. Then, we evaluated the correlation of the best-performing tau assay (NT1-tau) with clinical severity and functional decline (using the MRC Prion Disease Rating Scale) in a longitudinal CJD cohort (n = 145). In a cross-sectional study, tau measured in CSF with the NT1 and mid-region Simoa assays, separated CJD (n = 15) from AD (n = 18) and controls (n = 21) with a diagnostic accuracy (AUCs: 0.98–1.00) comparable to or better than neurofilament light chain (NfL; AUCs: 0.96–0.99). In plasma, NT1-measured tau was elevated in CJD (n = 5) versus AD (n = 15) and controls (n = 15). Moreover, in CJD plasma (n = 145) NT1-tau levels correlated with stage and rate of disease progression, and the effect on clinical progression was modified by the PRNP codon 129. Our findings suggest that plasma NT1-tau shows promise as a minimally invasive diagnostic and prognostic biomarker of CJD, and should be further investigated for its potential to monitor disease progression and response to therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|